Kariva

Birth Control, Acne Vulgaris, Folate supplementation therapy + 5 more
Treatment
1 FDA approval
20 Active Studies for Kariva

What is Kariva

EthinylestradiolThe Generic name of this drug
Treatment SummaryDesogestrel is a type of steroid hormone used in combination with estrogen to prevent pregnancy. It was first developed in 1972 by Organon USA Inc and approved by the FDA in 1992. Desogestrel is derived from naturally occurring plant steroids and works by inhibiting ovulation and thickening cervical mucus to prevent sperm from entering the uterus.
LOESTRIN Fe 1.5/30is the brand name
Kariva Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
LOESTRIN Fe 1.5/30
Ethinylestradiol
1973
679

Approved as Treatment by the FDA

Ethinylestradiol, also known as LOESTRIN Fe 1.5/30, is approved by the FDA for 1 uses including Birth Control .
Birth Control
Used to treat Contraception in combination with Levonorgestrel

Effectiveness

How Kariva Affects PatientsDesogestrel works by preventing ovulation in 97% of cycles and has a Pearl failure rate of 0.17 per 100 women-years. It can also change the endometrium and affect other hormones. However, taking desogestrel can increase the risk of venous thromboembolism due to increased blood coagulation factors. Luckily, it does not significantly raise the level of total cholesterol, usually staying within 10%.
How Kariva works in the bodyDesogestrel prevents pregnancy by entering the cell and binding to the progesterone receptor. This binding triggers a chain of events that stops an egg from being released. Its active metabolite, etonogestrel, has a high progestational activity with minimal androgenicity.

When to interrupt dosage

The accepted dosage of Kariva is contingent upon the diagnosed condition, for example Birth Control, Nursing Women and Hormonal Contraception. The amount of dosage also depends on the mode of delivery (e.g. Kit or Kit; Tablet - Oral) outlined in the table beneath.
Condition
Dosage
Administration
Osteoporosis
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Folate supplementation therapy
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Patient desires oral contraception for birth control
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Acne Vulgaris
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Birth Control
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Acne Vulgaris
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Hormonal Contraception
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Menopause
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral

Warnings

Kariva has twenty-five contraindications, hence it should not be combined with the conditions in the following table.Kariva Contraindications
Condition
Risk Level
Notes
Smoking
Do Not Combine
Metrorrhagia
Do Not Combine
estrogen-sensitive cancer
Do Not Combine
Thrombophlebitis
Do Not Combine
Venous Thrombosis
Do Not Combine
Venous Thrombosis
Do Not Combine
Pulse Frequency
Do Not Combine
Breast
Do Not Combine
Coronary Artery Disease
Do Not Combine
high risk of arterial thrombotic disease
Do Not Combine
Thromboembolism
Do Not Combine
Coronary Disease
Do Not Combine
Hypersensitivity
Do Not Combine
Pulse Frequency
Do Not Combine
Adrenal Insufficiency
Do Not Combine
major surgery with prolonged immobilization
Do Not Combine
Pulse Frequency
Do Not Combine
Hypertension
Do Not Combine
undiagnosed abnormal genital bleeding
Do Not Combine
Breast Cancer
Do Not Combine
Liver Neoplasms
Do Not Combine
Deep Vein Thrombosis
Do Not Combine
Fibrosis
Do Not Combine
Breast
Do Not Combine
Renal Insufficiency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Ethinylestradiol may interact with Pulse Frequency
There are 20 known major drug interactions with Kariva.
Common Kariva Drug Interactions
Drug Name
Risk Level
Description
Anastrozole
Major
The therapeutic efficacy of Anastrozole can be decreased when used in combination with Ethinylestradiol.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Ethinylestradiol.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Ethinylestradiol.
Belinostat
Major
The metabolism of Belinostat can be increased when combined with Ethinylestradiol.
Binimetinib
Major
The metabolism of Binimetinib can be increased when combined with Ethinylestradiol.
Kariva Toxicity & Overdose RiskLarge amounts of desogestrel have been known to have strong hormonal effects, but cause no long-term harm. The reported toxic dose in rats is higher than 2000mg/kg. An overdose of desogestrel may cause nausea and withdrawal bleeding, but there are no serious side effects. Reports have not linked desogestrel to an increased risk of breast cancer, but there may be an increased risk of cervical intra-epithelial neoplasia. However, these results are not conclusive.
image of a doctor in a lab doing drug, clinical research

Kariva Novel Uses: Which Conditions Have a Clinical Trial Featuring Kariva?

38 active clinical trials are being conducted to assess the potential of Kariva to aid Nursing Women, facilitate Birth Control and support Hormonal Contraception.
Condition
Clinical Trials
Trial Phases
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2
Hormonal Contraception
0 Actively Recruiting
Folate supplementation therapy
0 Actively Recruiting
Patient desires oral contraception for birth control
0 Actively Recruiting
Osteoporosis
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Menopause
0 Actively Recruiting

Kariva Reviews: What are patients saying about Kariva?

5Patient Review
6/28/2016
Kariva for Acne
I was really pleased with how this pill worked. My skin cleared up almost entirely, and I experienced no side effects whatsoever.
5Patient Review
1/10/2018
Kariva for Birth Control
I've used this for 20 years with no problems, and then got pregnant the month after I stopped.
5Patient Review
2/19/2021
Kariva for Birth Control
I've been on Kariva for 8 months and love it. I am also on Accutane and needed to get on BC, but I haven't experienced any bad side effects. I take the pill at the same time everyday and it works great. My period comes at the same time every month and only lasts around 4 days. I think it also helped with lightening my flow. I plan to stay on the drug even after I am off of Accutane.
4.7Patient Review
3/26/2015
Kariva for Painful Periods
I've been taking Kariva for a little over a year now. I experienced some bloating early on, but it quickly subsided. Additionally, I have not noticed any negative changes in my mood or sex drive. However, there is one spider vein that has become more prominent recently. This concerns me as it may be indicative of deeper issues.
4.7Patient Review
5/4/2015
Kariva for Birth Control
This has been a really great medication for me with few negative side effects. I also appreciate that it is still effective even when I am not able to take it at the exact same time each day.
4.3Patient Review
2/24/2016
Kariva for Birth Control
I was on Kariva for nine years and it was totally effective for me. I didn't always take it at the same time every day, but when I started dating someone who noticed, I began to be more consistent with taking it.
3.7Patient Review
9/10/2019
Kariva for Painful Periods
The first three months were okay, but after that I started getting migraines, horrible sleep, and tons of breast cysts. The cysts got so bad that I'm now constantly running between doctors trying to figure out if any of them are cancerous lumps. This medicine has ruined my summer and my life in general. CVS switched me to this after I was on Azurette without issues for 2 years. I've completely stopped taking it and I'm already seeing improvement.
3.7Patient Review
3/23/2019
Kariva for Absence of Menstrual Periods
I tried this pill in order to help with my irregular periods and acne, but it unfortunately just made my skin worse. On top of that, it gave me anxiety and paranoia which then bled into other aspects of my life. I'll be discontinuing use of this birth control as soon as possible.
3.7Patient Review
3/31/2015
Kariva for Birth Control
I was switched to Kariva by my doctor because of the increased risk of blood clots with Beyaz (which I never had and don't smoke). I took it for 3 months and experienced decreased libido, BAD acne, headaches and constant hunger - causing me to gain more weight. I am changing to another pill; this one just doesn't work well for me. With Beyaz, I only experienced mood swings...I wish they would've just left me on that!!
3.7Patient Review
8/3/2022
Kariva for Birth Control
I started having negative experiences with this medication after about three months. I was always hungry, tired, and sleeping so much that I would sometimes miss my pill the next morning. My libido decreased to the point where I didn't even want my boyfriend of 1 1/2 years to kiss me. I gained 5-10lbs. I'm definitely going to look into getting this switched.
3Patient Review
6/11/2015
Kariva for Acne
My grand daughter used this for about one year and developed five deep vein thrombosis in her leg and pulmonary embolism. It was life threatening. The doctors ruled out any other cause.
2.7Patient Review
3/15/2022
Kariva for Abnormally Long or Heavy Periods
There are some definite pros to this treatment - my skin looked amazing after using it for a few months. However, there were also some significant cons that led me to stop taking the medication. These included weight gain, loss of sex drive, vaginal dryness, constant fatigue, anxiety, and nonstop spotting. I stopped taking Kariva a few days ago and have already noticed an improvement in my energy level and weight.
2Patient Review
9/28/2021
Kariva for Birth Control
I had awful side effects while taking this birth control. I would get depressed, have hot flashes, and put on weight. Even though it was effective in preventing pregnancy, I would never take it again because of how terrible I felt.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about kariva

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Kariva a good birth control?

"It seemed to work well for a few months, but I gained about 10 pounds. The side effects weren’t really worth it, so I switched to another pill.”

While some reviewers found Kariva to be an effective treatment for Birth control, others found the side effects not worth the trouble, reporting weight gain and negative experiences."

Answered by AI

What is the generic name for Kariva?

"Kariva is a birth control pill that contains two female hormones, a progestin and an estrogen. It is a generic version of the brand-name birth control pill, Mircette."

Answered by AI

What is Kariva used for?

"This medication is a combination of two hormones, desogestrel and ethinyl estradiol, which are used to prevent pregnancy."

Answered by AI

What kind of birth control pill is Kariva?

"- Feb 20, 2022

Kariva is a combination birth control pill that uses female hormones to prevent ovulation. It also causes changes in cervical mucus and the uterine lining, making it harder for sperm to reach the uterus and for a fertilized egg to attach to it."

Answered by AI

Clinical Trials for Kariva

Image of University of California, San Diego in La Jolla, United States.

Lidocaine for Pain Control in Birth Control

18 - 50
Female
La Jolla, CA
The goal of this research study is to learn more about how different uses of a numbing medication might affect pain levels while getting an IUD placed. The investigators are also studying participants opinions of their clinicians' empathy. The investigators are inviting patients who arrive at their clinic visit seeking an IUD. Usually, at University of California, San Diego (UCSD), for patients who have never delivered a baby, clinicians use a buffered paracervical block for before IUD placement. The purpose of this research study is to investigate whether a "buffered" (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) paracervical block (numbing medication given on both sides of the cervix) is effective in reducing pain during IUD placement in individuals with prior C-sections, the difference between buffered and unbuffered for nulliparous patients, and whether a medicated gel reduces pain with the paracervical block.
Recruiting
Paid Trial
University of California, San DiegoSheila K Mody, MD, MPH
Image of EmpoweRx, Inc in Del Mar, United States.

HAPPI Software for Birth Control Access

18+
All Sexes
Del Mar, CA
The goal of this clinical trial is to learn if use of the HAPPI software can improve pharmacist-provided birth control services. The main questions it aims to answer are: 1. Does the HAPPI software make it easier for pharmacists to provide birth control services in their pharmacy? 2. Does the HAPPI software make it easier for patients to access birth control? Researchers will compare pharmacists' implementation and patients' access when using the HAPPI software and when not using the HAPPI software to see if the software improves implementation and access. Participants will include pharmacists and patients. Pharmacists will be asked to provide birth control services as normal while using the HAPPI software. Patients will be asked to receive birth control services from a pharmacist as normal, while using the HAPPI software.
Recruiting
Has No Placebo
EmpoweRx, Inc
Image of Calabasas Pharmacy in Calabasas, United States.

Electronic Health Record Platform for Birth Control

18 - 51
Female
Calabasas, CA
Hormonal contraceptives are medications that require a prescription, traditionally from a physician or advanced practice provider. Over the past decade, pharmacists have gained the authority to prescribe contraceptives in many states, allowing patients to access these medications directly in pharmacies without first seeing another healthcare provider. The Pharmacist Resource to Implement Services as Modules (PRISM) is an Electronic Health Record platform designed to streamline workflows and provide clinical decision support, making it easier and safer to deliver clinical services in community pharmacies. This pilot study will evaluate patient-reported outcomes for women receiving contraceptive services from pharmacists using the PRISM platform at five community pharmacies across the United States over a 12-week period. The study will assess the quality of care, contraception continuation and failure rates, side effect rates, preventative healthcare utilization, and overall patient experience with pharmacy contraceptive services.
Waitlist Available
Has No Placebo
Calabasas Pharmacy (+4 Sites)OvaryIt, LLC
Have you considered Kariva clinical trials? We made a collection of clinical trials featuring Kariva, we think they might fit your search criteria.Go to Trials
Image of Jackson State University/Department of Behavioral & Environmental Health in Jackson, United States.

PEN-3 Intervention for Postpartum Depression

18 - 45
Female
Jackson, MS
Maternal mortality in the United States is higher than in peer nations and has not decreased since 1990. Beyond mortality, severe maternal mortality impacts far too many women. Not only are these high rates alarming, but notable racial/ethnic and socioeconomic disparities exist. These inequities are highly regional, with women living in the rural southeast part of the United States, including the Mississippi Delta, having the highest rates of maternal mortality and morbidity. Unfortunately, these disparities have proven to be stubbornly resistant to interventions, necessitating an innovative multifaceted approach focused on community practice, building trust, and prioritizing patient voices. To meet this need, this proposal aims to establish the Mississippi Delta Research Center of Excellence for Maternal Health with the goal of addressing preventable maternal mortality, decreasing severe maternal morbidity, and promoting maternal health equity in partnership with the Mississippi Delta community. This patient-clinical linkages intervention study will evaluate the effectiveness of a multilevel and multisector communication and health literacy strategy to increase trust and engagement in postpartum healthcare among women in the Mississippi Delta, with a specific focus on Black women, their families, and their communities. These research projects both have the overarching goal of partnering with the community to determine and meet the needs of pregnant and postpartum women in the Mississippi Delta and address the disparities within maternity health and health care outcomes.
Recruiting
Has No Placebo
Jackson State University/Department of Behavioral & Environmental HealthMary Shaw, PhD
Image of University of Colorado Anschutz Medical Campus in Aurora, United States.

Birth Control Pills and DNA Interaction

18 - 45
Female
Aurora, CO
The goal of this clinical trial is to evaluate how differences in specific parts of our DNA can influence how individual bodies break down the hormones contained within oral contraceptive pills, which could affect how well these birth control pills work to prevent pregnancy. The investigators are also interested in exploring how these differences in our DNA can also explain why patients taking the exact same formulation of birth control pill will experience very different side effects. The main questions it aims to answer are: * Do individuals with the CYP3A7\*1C variant have increased metabolism of both desogestrel and ethinyl estradiol when taking a combined oral contraceptive pill? * Do individuals with the CYP3A7\*1C variant experience higher rates of breakthrough ovulation while taking a desogestrel/ethinyl estradiol combined oral contraceptive pill? * What novel genetic loci are associated with alterations in steroid hormone pharmacokinetics and pharmacodynamics among a larger cohort of combined oral contraceptive pill users? Participants will take a specific formulation of combined oral contraceptive pill (desogestrel/ethinyl estradiol) and undergo the following procedures: * Blood draw to measure the amount of progestin and estrogen in their system from the combined oral contraceptive pill * Questionnaires to assess side effects possibly caused by the combined oral contraceptive pill * Blood draw to measure endogenous hormone levels and biomarkers that may be affected by the combined oral contraceptive pill * A transvaginal ultrasound to measure any ovarian follicles (optional procedure)
Phase 4
Recruiting
University of Colorado Anschutz Medical Campus (+2 Sites)Aaron M Lazorwitz, MD, PhD
Have you considered Kariva clinical trials? We made a collection of clinical trials featuring Kariva, we think they might fit your search criteria.Go to Trials
Image of Greater Boston Health Center in Boston, United States.

SBIRT for Alcohol and Substance Use Disorders

18+
All Sexes
Boston, MA
The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic. The main questions it aims to answer are: * Does SBIRT impact patients' alcohol and substance use, SRH, mental health, physical health, quality of life, and wellbeing? * Does SBIRT effectiveness differ by ethnicity, socioeconomic status, age, gender, and urbanicity? * Does SBIRT effectiveness differ by delivery mode (in-person vs. telemedicine)? Participants will receive in-person and telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months. Researchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.
Recruiting
Has No Placebo
Greater Boston Health Center (+3 Sites)Kelli S Hall, MD
Image of OHSU in Portland, United States.

Progestin Contraceptives for Birth Control Effects

18 - 40
Female
Portland, OR
The purpose of the study is to learn more about menstrual changes in progestin contraception users. The investigators are hoping to find out what changes in the endometrium lead to different bleeding patterns during the first year of progestin contraception use. Participants will choose to receive the contraceptive implant (Etonogestrel implant also called Nexplanon) or the contraceptive injectable (Depo-medroxyprogesterone acetate (DMPA) also called Depo-Provera) for up to 12 months. They will be asked to have 4 endometrial biopsies over the course of the study, as well as blood draws, physical exams, and pregnancy tests. Participants will also use a daily text message or email diary to report bleeding patterns. This study's plan is to comprehensively phenotype bleeding patterns and profile the entire endometrium using single-cell RNA seq data (sCRNAseq).
Phase < 1
Recruiting
OHSUAlison Edelman, MD
Have you considered Kariva clinical trials? We made a collection of clinical trials featuring Kariva, we think they might fit your search criteria.Go to Trials